Ciproxin licensed for UTI in children

The licence for Ciproxin (ciprofloxacin) has been extended to include the second- and third-line treatment of complicated UTIs and pyelonephritis in children and adolescents aged between 1-17 years.

The dose is 10-20mg/kg orally every 12 hours up to a maximum of 750mg per dose. The recommended duration of treatment is 10-21 days.

View Ciproxin drug record

Further information: Bayer plc

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Added: azathioprine.
Use our constantly updated...

New MIMS section offers external resources to benefit your practice

New MIMS section offers external resources to benefit your practice

MIMS Hosted is a new section of the MIMS website providing...

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

New headache toolkit offers tips to improve management in primary care

New headache toolkit offers tips to improve management in primary care

GPs should use standardised headache assessment criteria...